Glaukos Q2 Sales Surge 50% to $185.6M, Full-Year Guidance Raised to $680-$700M
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (3.0× avg).
Summary
Glaukos reported Q2 2026 net sales of $185.6 million, up 50% year-over-year, and raised full-year guidance to $680-$700 million. Gross margin improved to 82%, and the operating loss narrowed. The results highlight strong iDose TR adoption and the early commercial launch of Epioxa.
Key Events · Earnings and Guidance · GKOS
-
Q2 Sales Surge 50%
Net sales reached $185.6 million, up 50% from $124.1 million a year ago, driven by 64% growth in U.S. glaucoma sales from iDose TR and a 48% increase in corneal health sales from the Epioxa launch.
-
Full-Year Guidance Raised
Management raised 2026 revenue guidance to $680-$700 million, up from prior expectations, reflecting strong momentum in iDose TR and Epioxa.
-
Gross Margin Expands to 82%
Gross margin improved to 82% from 78% a year ago, benefiting from higher-margin iDose TR and Epioxa sales, despite increased amortization of intangible assets.
-
Operating Loss Narrows
Loss from operations narrowed to $17.3 million from $22.7 million, as revenue growth outpaced a 41% increase in operating expenses driven by higher stock-based compensation and commercial investments.
Analysis · GKOS · Industrial Applications And Services
A standout quarter for Glaukos saw net sales jump 50% year-over-year to $185.6 million, fueled by 64% growth in U.S. glaucoma sales from iDose TR adoption. Gross margin expanded to 82%, and the operating loss narrowed. Reflecting confidence in the commercial ramp of iDose TR and the controlled launch of Epioxa, management raised full-year 2026 guidance to $680-$700 million. The stock is trading near its 52-week high, underscoring market optimism, but the filing also flags risks: proposed LCDs from five MACs could restrict iDose TR coverage, and the transition from Photrexa to Epioxa may cause near-term disruption in corneal health. With $286 million in cash and investments, the company has ample runway to fund its growth initiatives.
At the time of this filing, GKOS was trading at $175.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $166.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.